Some studies have surveyed non-invasive parameters including anthropometric measurements (e.g., body mass index [BMI] and waist circumference) (4–6), body fat distribution (e.g., visceral and subcutaneous fat) (7, 8), biochemical data (e.g., homeostasis model of assessment values for insulin resistance [HOMA-IR] and hypertriglyceridemia), and adipokine patterns (e.g., leptin and adiponectin) in NAFLD patients (9–12). This evidence concerns the gene LEP and metabolic dysfunction-associated steatotic liver disease.